1. Home
  2. PRAX vs ADC Comparison

PRAX vs ADC Comparison

Compare PRAX & ADC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$344.19

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Logo Agree Realty Corporation

ADC

Agree Realty Corporation

HOLD

Current Price

$75.50

Market Cap

9.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
ADC
Founded
2015
1971
Country
United States
United States
Employees
N/A
90
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
9.2B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PRAX
ADC
Price
$344.19
$75.50
Analyst Decision
Strong Buy
Buy
Analyst Count
15
14
Target Price
$572.13
$84.50
AVG Volume (30 Days)
332.8K
910.3K
Earning Date
05-08-2026
04-21-2026
Dividend Yield
N/A
4.12%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$12.01
Revenue Next Year
$7,758.26
$9.90
P/E Ratio
N/A
$43.33
Revenue Growth
N/A
N/A
52 Week Low
$35.21
$69.56
52 Week High
$358.76
$82.08

Technical Indicators

Market Signals
Indicator
PRAX
ADC
Relative Strength Index (RSI) 55.46 44.07
Support Level $282.49 $75.38
Resistance Level $353.86 $75.68
Average True Range (ATR) 20.50 1.02
MACD 0.17 -0.02
Stochastic Oscillator 71.68 41.24

Price Performance

Historical Comparison
PRAX
ADC

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About ADC Agree Realty Corporation

Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.

Share on Social Networks: